製品の概要

  • 製品名Anti-Progesterone antibody [2H4]
    Progesterone 一次抗体 製品一覧
  • 製品の詳細
    Rat monoclonal [2H4] to Progesterone
  • アプリケーション適用あり: RIAmore details
  • 種交差性
    交差種: Human
  • 免疫原

    Progesterone 7 (Human) conjugated to BSA

  • 特記事項Do not store in a frost-free freezer.

製品の特性

  • 製品の状態Liquid
  • 保存方法Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
  • バッファーPreservative: 15mM Sodium Azide
    Constituents: Tissue culture supernatant
  • 精製度Tissue culture supernatant
  • 特記事項(精製)Cell culture supernatant.
  • ポリ/モノモノクローナル
  • クローン名2H4
  • アイソタイプIgG1
  • 研究分野

アプリケーション

Our Abpromise guarantee covers the use of ab11001 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

アプリケーション Abreviews 特記事項
RIA
  • 追加情報RIA: Use at an assay dependent dilution.

    Reagents
    (A) Buffer: 0.05 M Tris-HCl, pH 8.0, with 0.1M NaCl, 0.1% gelatin, and 0.1% sodium azide.
    (B) Dextran-Coated Charcoal: 0.5% (w/v) Dextran T-70 in buffer without gelatin. Mix for 1 hour at 4 °C prior to use.
    (C) Standards: Prepare a standard solution of 1µg/ml of progesterone in absolute ethanol. Dilute an aliquot in buffer to a concentration of 5 ng/ml. Six further serial doubling dilutions are prepared in buffer from the 5 ng/ml standard giving the following concentrations: 2.5, 1.25, 0.63, 0.31, 0.15, and 0.078 ng/ml.
    (D) Radiolabeled progesterone: Prepare a fresh solution of 70,000-100,000 dpm/ml of tritiated progesterone.

    RIA Protocol
    1. The working dilution of the product is prepared with 0.05 M Tris-HCl buffer, pH 8.0, with 0.1 M NaCl, 0.1% gelatin and 0.1% sodium azide.
    2. In polypropylene test tubes add 0.1 ml of sample or standard and 0.5 ml of monoclonal antibody, diluted to working dilution, and mix.
    3. Incubate tubes at room temperature for 30 minutes.
    4. Add 0.1 ml of tritiated progesterone to all tubes and mix. Incubate at 37 °C for 60 minutes.
    5. Cool at 4 °C for 15 minutes.
    6. Add 0.2 ml of dextran coated charcoal solution to each tube, excluding the total tube to which 0.2 ml of buffer is added.
    7. Vortex all tubes and incubate at 4 °C for 10 minutes. Centrifuge at 4 °C for 15 minutes at 3000 rpm.
    8. Remove 0.25 ml of the supernatant and add 3 ml of scintillation fluid. Determine the amount of radioactivity present.

    Not tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • ターゲット情報

    • 関連性Progesterone plays a central role in the reproductive events associated with the establishment and maintenance of pregnancy. Progesterone receptor, a member of the steroid receptor superfamily, mediates the physiologic effects of progesterone. The PGR gene uses separate promoters and translational start sites to produce 2 isoforms, PRA and PRB, which are identical except for an additional 165 amino acids present only in the N terminus of PRB. Although PRA and PRB share several structural domains, they are distinct transcription factors that mediate their own response genes and physiologic effects with little overlap. It is composed of three domains: a modulating N terminal domain, a DNA binding domain and a C terminal steroid binding domain. Progesterone levels 1. men 30-60 pg/0.1ml 2. women pre ovulatory phase: 20-160 pg/0.1ml; ovulatory phase: 1,000-1,700 pg/0.1ml; post ovulatory phase: 1,000-1,700 pg/0.1ml; Pregnant: 16-18 weeks: 300-800 pg/0.1ml; 28-30 weeks: 6,500-14,700 pg/0.1ml; 38-40 weeks: 12,000-19,000 pg/0.1ml.
    • 細胞内局在Secreted
    • 別名
      • Pregn 4 ene 3 20 dione antibody

    Anti-Progesterone antibody [2H4] (ab11001) 使用論文

    ab11001 has not yet been referenced specifically in any publications.

    Product Wall

    There are currently no Abreviews or Questions for ab11001.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"